Andrew Fein

H.C. Wainwright & Co.

Image: Andrew Fein

In May 2013, Andrew Fein joined H.C. Wainwright & Co. as managing director and senior biotechnology analyst to cover companies in the biotechnology and life sciences sectors. He has 13 years of experience in healthcare and biotechnology equity research. He was previously a senior analyst at Chardan Capital Markets and held prior research positions at Jefferies & Co., Piper Jaffrey, Collins Stewart, Leerink Swann LLC and J.P. Morgan.

Recent Articles

Pharma Co. Reports Positive Data for Leukemia Combination Therapy 12/06/2023

Recently, Syros Pharmaceuticals Inc. announced positive data for its Leukemia Combination Therapy, noted an H.C. Wainwright & Co. report.

Recent Quotes

"ATNM's two clinical programs offer a cheap long opportunity for investors interested in AML therapeutics."

— Andrew Fein, H.C. Wainwright & Co. (6/2/16)
more >

Due to permission requirements, not all quotes are shown.